Literature DB >> 31687831

Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure.

Domenico Luca Grieco1,2, Luca S Menga1,2, Valeria Raggi1,2, Filippo Bongiovanni1,2, Gian Marco Anzellotti1,2, Eloisa S Tanzarella1,2, Maria Grazia Bocci1,2, Giovanna Mercurio1,2, Antonio M Dell'Anna1,2, Davide Eleuteri1,2, Giuseppe Bello1,2, Riccardo Maviglia1,2, Giorgio Conti1,2, Salvatore Maurizio Maggiore3, Massimo Antonelli1,2.   

Abstract

Rationale: High-flow nasal cannula (HFNC) and helmet noninvasive ventilation (NIV) are used for the management of acute hypoxemic respiratory failure.
Objectives: Physiological comparison of HFNC and helmet NIV in patients with hypoxemia.
Methods: Fifteen patients with hypoxemia with PaO2/FiO2 < 200 mm Hg received helmet NIV (positive end-expiratory pressure ≥ 10 cm H2O, pressure support = 10-15 cm H2O) and HFNC (50 L/min) in randomized crossover order. Arterial blood gases, dyspnea, and comfort were recorded. Inspiratory effort was estimated by esophageal pressure (Pes) swings. Pes-simplified pressure-time product and transpulmonary pressure swings were measured.Measurements and Main
Results: As compared with HFNC, helmet NIV increased PaO2/FiO2 (median [interquartile range]: 255 mm Hg [140-299] vs. 138 [101-172]; P = 0.001) and lowered inspiratory effort (7 cm H2O [4-11] vs. 15 [8-19]; P = 0.001) in all patients. Inspiratory effort reduction by NIV was linearly related to inspiratory effort during HFNC (r = 0.84; P < 0.001). Helmet NIV reduced respiratory rate (24 breaths/min [23-31] vs. 29 [26-32]; P = 0.027), Pes-simplified pressure-time product (93 cm H2O ⋅ s ⋅ min-1 [43-138] vs. 200 [168-335]; P = 0.001), and dyspnea (visual analog scale 3 [2-5] vs. 8 [6-9]; P = 0.002), without affecting PaCO2 (P = 0.80) and comfort (P = 0.50). In the overall cohort, transpulmonary pressure swings were not different between treatments (NIV = 18 cm H2O [14-21] vs. HFNC = 15 [8-19]; P = 0.11), but patients exhibiting lower inspiratory effort on HFNC experienced increases in transpulmonary pressure swings with helmet NIV. Higher transpulmonary pressure swings during NIV were associated with subsequent need for intubation.Conclusions: As compared with HFNC in hypoxemic respiratory failure, helmet NIV improves oxygenation, reduces dyspnea, inspiratory effort, and simplified pressure-time product, with similar transpulmonary pressure swings, PaCO2, and comfort.

Entities:  

Keywords:  acute respiratory failure; high-flow nasal oxygen; noninvasive ventilation

Mesh:

Year:  2020        PMID: 31687831     DOI: 10.1164/rccm.201904-0841OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  39 in total

Review 1.  High-flow nasal cannulae for respiratory support in adult intensive care patients.

Authors:  Amanda Corley; Claire M Rickard; Leanne M Aitken; Amy Johnston; Adrian Barnett; John F Fraser; Sharon R Lewis; Andrew F Smith
Journal:  Cochrane Database Syst Rev       Date:  2017-05-30

2.  ARDS in COVID-19 and beyond: Let's keep our eyes on the goal instead of the straw man.

Authors:  Jarrod Mosier; Bhupinder Natt; Josh Malo
Journal:  J Intensive Care Soc       Date:  2020-11-19

3.  Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19: The HELMET-COVID Randomized Clinical Trial.

Authors:  Yaseen M Arabi; Sara Aldekhyl; Saad Al Qahtani; Hasan M Al-Dorzi; Sheryl Ann Abdukahil; Mohammed Khulaif Al Harbi; Eman Al Qasim; Ayman Kharaba; Talal Albrahim; Mohammed S Alshahrani; Abdulrahman A Al-Fares; Ali Al Bshabshe; Ahmed Mady; Zainab Al Duhailib; Haifa Algethamy; Jesna Jose; Mohammed Al Mutairi; Omar Al Zumai; Hussain Al Haji; Ahmed Alaqeily; Zohair Al Aseri; Awad Al-Omari; Abdulaziz Al-Dawood; Haytham Tlayjeh
Journal:  JAMA       Date:  2022-09-20       Impact factor: 157.335

4.  Helmet noninvasive support in hypoxemic respiratory failure.

Authors:  Domenico Luca Grieco; Bhakti K Patel; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2022-06-17       Impact factor: 41.787

Review 5.  Update in Critical Care 2020.

Authors:  Robinder G Khemani; Jessica T Lee; David Wu; Edward J Schenck; Margaret M Hayes; Patricia A Kritek; Gökhan M Mutlu; Hayley B Gershengorn; Rémi Coudroy
Journal:  Am J Respir Crit Care Med       Date:  2021-05-01       Impact factor: 21.405

Review 6.  Effectiveness and Harms of High-Flow Nasal Oxygen for Acute Respiratory Failure: An Evidence Report for a Clinical Guideline From the American College of Physicians.

Authors:  Arianne K Baldomero; Anne C Melzer; Nancy Greer; Brittany N Majeski; Roderick MacDonald; Eric J Linskens; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2021-04-27       Impact factor: 25.391

7.  High-flow nasal cannulae for respiratory support in adult intensive care patients.

Authors:  Sharon R Lewis; Philip E Baker; Roses Parker; Andrew F Smith
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

8.  Noninvasive Ventilation by Helmet vs Face Mask in COVID-19 Pneumonia: Emerging Evidence and Need of the Hour.

Authors:  Puneet Jain
Journal:  Indian J Crit Care Med       Date:  2022-03

Review 9.  Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions.

Authors:  Elena Spinelli; Tommaso Mauri; Jeremy R Beitler; Antonio Pesenti; Daniel Brodie
Journal:  Intensive Care Med       Date:  2020-02-03       Impact factor: 17.440

Review 10.  Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS.

Authors:  Domenico Luca Grieco; Salvatore Maurizio Maggiore; Oriol Roca; Elena Spinelli; Bhakti K Patel; Arnaud W Thille; Carmen Sílvia V Barbas; Marina Garcia de Acilu; Salvatore Lucio Cutuli; Filippo Bongiovanni; Marcelo Amato; Jean-Pierre Frat; Tommaso Mauri; John P Kress; Jordi Mancebo; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2021-07-07       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.